As of 2026-03-24, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (138.35) USD. This relative valuation is based on P/E multiples. With the latest stock price at 20.27 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -782.5%.
The range of the Relative Valuation is (132.58) - (152.33) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.3x - 27.2x | 24.5x |
| Forward P/E multiples | 21.1x - 25.6x | 22.0x |
| Fair Price | (132.58) - (152.33) | (138.35) |
| Upside | -754.1% - -851.5% | -782.5% |
| Date | P/E |
| 2026-03-20 | -3.34 |
| 2026-03-19 | -3.43 |
| 2026-03-18 | -3.44 |
| 2026-03-17 | -3.63 |
| 2026-03-16 | -3.67 |
| 2026-03-13 | -3.59 |
| 2026-03-12 | -3.65 |
| 2026-03-11 | -3.73 |
| 2026-03-10 | -3.84 |
| 2026-03-09 | -3.80 |
| 2026-03-06 | -3.57 |
| 2026-03-05 | -3.61 |
| 2026-03-04 | -3.66 |
| 2026-03-03 | -3.71 |
| 2026-03-02 | -3.87 |
| 2026-02-27 | -3.93 |
| 2026-02-26 | -3.87 |
| 2026-02-25 | -3.85 |
| 2026-02-24 | -3.82 |
| 2026-02-23 | -3.78 |
| 2026-02-20 | -3.82 |
| 2026-02-19 | -3.67 |
| 2026-02-18 | -3.44 |
| 2026-02-17 | -3.39 |
| 2026-02-13 | -3.45 |
| 2026-02-12 | -3.95 |
| 2026-02-11 | -4.01 |
| 2026-02-10 | -4.07 |
| 2026-02-09 | -4.01 |
| 2026-02-06 | -4.15 |
| 2026-02-05 | -4.00 |
| 2026-02-04 | -4.15 |
| 2026-02-03 | -4.17 |
| 2026-02-02 | -4.16 |
| 2026-01-30 | -4.05 |
| 2026-01-29 | -4.08 |
| 2026-01-28 | -4.11 |
| 2026-01-27 | -4.14 |
| 2026-01-26 | -4.09 |
| 2026-01-23 | -4.07 |
| 2026-01-22 | -3.93 |
| 2026-01-21 | -3.82 |
| 2026-01-20 | -3.80 |
| 2026-01-16 | -3.78 |
| 2026-01-15 | -3.95 |
| 2026-01-14 | -4.05 |
| 2026-01-13 | -4.05 |
| 2026-01-12 | -4.10 |
| 2026-01-09 | -3.78 |
| 2026-01-08 | -3.90 |